 |
|
|
 |
|
Rationale:
- The postoperative assessment provides an opportunity for the physician to provide risk factor reduction management to prevent
progression of cardiac and diabetic complications.
|
|
Evidence:
- In the Steno-2 study, 160 patients were randomly assigned to usual care vs. intensive, targeted, multifactorial intervention
on modifiable risk factors for cardiovascular disease in patients with type 2 diabetes and microalbuminuria. Intensive risk
factor reduction targeted glycemic control, BP control, dyslipidemia, microalbuminuria, and secondary prevention of cardiovascular
disease with aspirin. Patients assigned to intensive therapy had a significantly lower risk of cardiovascular disease (hazard
ratio, 0.42) (64).
- Numerous randomized, controlled trials of drug management of lipid risk factors in diabetic patients have shown a favorable
effect on coronary and other atherosclerotic endpoints (65; 66; 67).
- Consensus guidelines recommend screening and treatment of lipid disorders for both primary and secondary prevention of CAD
(68). Specifically, supported by the intervention trials in diabetic populations, the American Diabetes Association recommends lipid-modifying therapy as part of the treatment regimen, the intensity of which varies depending on patient age,
the presence or absence of cardiovascular disease, and the presence or absence of risk factors (other than diabetes) for cardiovascular
disease (4).
- A post-test survey showed that simple postdischarge educational classes improved knowledge of CAD and health-promoting behaviors
(69).
- Studies on the prevention of foot ulceration using education in diabetes suggest that there may be a short-term benefit to
education (70).
|
|
Comments:
- The American Diabetes Association recommends statin therapy to achieve an LDL cholesterol target <100 mg/dL and a BP target
<130/80 mm Hg, ACE inhibitor or angiotensin receptor blocker therapy to achieve a BP target <130/80 mm Hg and reduce microalbuminuria,
and aspirin therapy if there are no contraindications. They also recommend yearly dilated eye exam and nightly foot exam.
- Starting medications that are considered the standard of care in patients with diabetes prevents vascular complications.
|
| FAQs |
|
|
|
Melanie E. Mabrey, MSN, ACNP, BC-ADM, is a consultant and speaker for Sanofi-Aventis Pharmaceuticals. Nadia A. Khan, MD has no financial relationships with pharmaceutical companies, biomedical device manufacturers, or health-care related organizations.
Susan E. Spratt, MD, is a consultant and speaker for Sanofi Aventis and Novo Nordisk. William A. Ghali, MD has no financial relationships with pharmaceutical companies, biomedical device manufacturers, or health-care related organizations.
Deborah Korenstein, MD, FACP, Co-Editor, PIER, has no financial relationships with pharmaceutical companies, biomedical device
manufacturers, or health-care related organizations. Richard B. Lynn, MD, FACP, Co-Editor, PIER, has no financial relationships
with pharmaceutical companies, biomedical device manufacturers, or health-care related organizations.
|
|
|
|
The information included herein should never be used as a substitute
for clinical judgment and does not represent an official position of
ACP. Because all PIER modules are updated regularly, printed web pages
or PDFs may rapidly become obsolete. Therefore, PIER users should
compare the date of the last update on the website with any printout
to ensure that the information being referred to is the most current
available.
|
PIER is copyrighted © 2012 by the American College of Physicians,
190 N. Independence Mall West, Philadelphia, PA 19106-1572, USA.
|
|
|